<p>Cadrenal Therapeutics（纳斯达克代码：CVKD）以一种冷静、几乎是外科手术般的方法进入了下半年的发展阶段。在大多数微型公司的宣传噪音中，Cadrenal 让其工作成果成为了焦点。试验准备向前推进，制造进展顺利，临床团队的领导层也得到了扩展。这些都没有引起太多关注，但每一个决策都让公司变得更加引人注目。安静的进展依然是进展，在 Cadrenal 的案例中，这为后续的一切奠定了基调。</p>
<p>Tecarfarin 是公司的一种药物候选者，处于抗凝治疗中一个临床上被忽视的领域。高风险的终末期肾病患者和复杂的心脏负担患者从现有药物中获得的结果并不如预期。Tecarfarin 旨在填补这一空白，提供与真实患者需求相符的控制性、可逆性和稳定性。</p>
<p>Cadrenal 的做法之所以引人注目，是因为这一切并没有被炒作。公司作为一个团队，首先专注于执行。它花了几个月的时间打下基础，建立结构，以便试验能够顺利推进到关键里程碑。这样深思熟虑的准备通常是出于一个原因：他们期望下一阶段的成果超出市场的预期。</p>
<p><strong>在无人关注时增长的管道</strong></p>
<p>随后是扩展。Cadrenal 增加了 Factor XIa 项目，旨在为急性医院护理提供新的途径，安全、可控的抗凝治疗将在此受到欢迎。这并不是一次表面上的收购。它拓宽了公司的机制范围，并创造了与 tecarfarin 互补而非竞争的机会。突然间，Cadrenal 在慢性和急性环境中都有了存在。</p>
<p>下一步更是提升了底线。Cadrenal 刚刚收购了 VLX-1005，这是一项针对肝素诱导的血小板减少症（HIT）的二期资产，获得了孤儿药和快速通道的认证。HIT 是罕见且危险的，迫切需要更好的治疗选择。像 Cadrenal 这样规模的公司收购具有这种监管定位的项目并不常见。这是战略性的。这使 Cadrenal 参与到几个月前根本无法接触的对话中。</p>
<p>所有这些投资组合的构建发生在股票继续交易，仿佛一切都没有改变。估值可能反映了过时的图景，而不是公司现在控制的更广泛的平台。这种脱节可能创造机会。最终，市场必须重新调整，因为跨越多个治疗环境的管道在临床势头建立后不会继续隐藏在微型公司领域。</p>
<p><strong>动量之前的时刻</strong></p>
<p>Cadrenal 正进入一个安静的基础工作可能转变为明显催化剂的阶段。试验准备正在排队，项目进展顺利，监管互动开始变得更加重要。每一步都有潜力重塑投资者对公司的看法。这是一个稳定、严谨的战略可能会获得回报的地方。公司在幕后进行了大量的工作。现在，周期转向市场可以实际看到的执行。</p>
<p>投资组合本身的结构旨在创造杠杆。Tecarfarin 的慢性护理定位满足了数十年来被忽视患者的现实需求。Factor XIa 项目将 Cadrenal 带入高价值的医院环境。VLX-1005 进入了一个即使是微小的改进也会引起严重关注的领域。每个资产通过展示一个具有一致愿景的公司而加强了彼此，而不是一个杂乱无章的管道。</p>
<p>安静的阶段似乎即将结束。Cadrenal 建立了一个平台，用数据的声音比头条新闻更响亮。CVKD 在屏幕上仍然显得微小，但其基础架构却暗示着不同。这不是一家等待相关性的公司，而是一家准备表达自己的公司。</p>
<p><strong>关于 Cadrenal Therapeutics, Inc.</strong></p>
<p>Cadrenal Therapeutics, Inc.正在开发差异化产品，以填补当前急性和慢性抗凝管理在稀有和高风险患者群体中的关键空白。它目前拥有三项临床阶段资产：VLX-1005，一种针对 HIT 的首创二期 12-LOX 抑制剂；tecarfarin，一种用于肾功能障碍或左心室辅助装置（LVAD）患者的口服维生素 K 拮抗剂（VKA）；以及 frunexian，一种用于急性医院环境的静脉小分子 Factor XIa 拮抗剂。有关更多信息，请访问 https://www.cadrenal.com/ 并在 LinkedIn 上与公司联系。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿中关于未来预期、计划和前景的任何声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些声明包括关于 Tecarfarin 旨在解决高风险终末期肾病患者和复杂心脏负担的可预测结果差距的声明，控制、可逆性和稳定性与真实患者需求相一致；花费数月时间奠定基础，建立结构以便试验能够进展到关键里程碑；公司预计下一阶段将比市场预期更大；Factor XIa 项目提供进入急性医院护理的新途径，股票估值创造机会；市场最终重新调整；临床势头增强；Cadrenal 进入一个安静的基础工作阶段，可能转变为可见的催化剂；试验准备就绪；项目进展开始；监管互动开始变得更加重要；每一步都有可能重塑投资者对公司的看法；这是一个稳定、严谨的战略可能会获得回报的地方；Tecarfarin 的慢性护理定位满足数十年来服务不足患者的现实需求；安静阶段似乎即将结束；CVKD 在屏幕上仍然显得微小，但基础架构暗示并非如此；并且是一家准备表达自己的公司。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括继续推进新型治疗药物以治疗或预防高风险患者的血栓形成的能力；包括推进 VLX-1005 用于 HIT 治疗的临床开发的能力；利用收购 Factor XIa 组合提供急性医院护理新途径的能力；按时成功完成临床试验并实现预期的结果和利益的能力；获得产品候选商业化的监管批准或遵守持续监管要求的能力，以及在公司截至 2024 年 12 月 31 日的 10-K 表格年度报告和公司随后向证券交易委员会提交的文件中描述的其他风险因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，公司特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><em><strong>准确性与披露声明：</strong> Hawk Point Media Group, LLC (HPM) 已被 IR Agency, Inc. 聘请，为 Cadrenal Therapeutics 提供新闻稿、编辑见解和数字媒体制作。此内容为赞助内容。对于 2025 年 12 月 12 日至 2025 年 12 月 16 日提供的服务，HPM 已通过电汇获得一万美元（USD）的报酬，用于与 Cadrenal Therapeutics 相关的内容创作和传播。此处包含的信息基于在创作时被认为准确和可靠的来源，包括公开可用的文件、公司披露和直接网站内容。此材料仅供信息参考，不应被解读为投资建议、推荐或购买或出售任何证券的要约。</em></p>
<p><em>在发布时，HPM 不拥有、购买、出售或交易所覆盖公司的证券。然而，聘请 HPM 的个人或组织可能持有 Cadrenal Therapeutics 的股份，并可能在覆盖期间出售这些股份。这种销售可能对股价施加下行压力，并导致投资者财务损失。</em></p>
<p><em>任何对该内容的复制、再分发或传播必须完整包含此披露。此声明是根据 1933 年证券法第 17(b) 条、联邦贸易委员会的认可指南以及其他适用法律提供的，适用于赞助通信和付费投资者内容。</em></p>
<p><strong>联系方式：</strong> info@hawkpointmedia.com</p>
<p><strong>来源：</strong> Cadrenal Therapeutics</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMw"/></p>

CVKD

<p>Cadrenal Therapeutics 正在悄然扩展其药物管线，专注于战略收购和试验准备。该公司旨在通过 Tecarfarin 和 VLX-1005 等药物解决高风险患者抗凝治疗中的空白。最近的收购和项目进展使 Cadrenal 具备了显著增长的潜力，可能会改变市场的看法。该公司正从基础工作转向可见的执行，利用其产品组合创造市场机会</p>

<p>Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While most microcaps lean on noise to stay visible, Cadrenal has let its work do the lifting. Trial preparation moved forward. Manufacturing advanced. Leadership depth expanded inside the clinical ranks. None of it screamed for attention, but each decision made the Company harder to ignore. Quiet progress is still progress, and in Cadrenal's case, it set the tone for everything that followed.</p>
<div class="lb-trans"><p>Cadrenal Therapeutics（纳斯达克代码：CVKD）以一种冷静、几乎是外科手术般的方法进入了下半年的发展阶段。在大多数微型公司的宣传噪音中，Cadrenal 让其工作成果成为了焦点。试验准备向前推进，制造进展顺利，临床团队的领导层也得到了扩展。这些都没有引起太多关注，但每一个决策都让公司变得更加引人注目。安静的进展依然是进展，在 Cadrenal 的案例中，这为后续的一切奠定了基调。</p>
</div><p>Tecarfarin, one of the Company's drug candidates, sits in one of the most clinically neglected segments of anticoagulation. High-risk patients with end-stage kidney disease and complex cardiac burdens simply do not get the predictable outcomes they should from today's drugs. Tecarfarin was designed to address that gap with control, reversibility, and stability that align with real patient needs.</p>
<div class="lb-trans"><p>Tecarfarin 是公司的一种药物候选者，处于抗凝治疗中一个临床上被忽视的领域。高风险的终末期肾病患者和复杂的心脏负担患者从现有药物中获得的结果并不如预期。Tecarfarin 旨在填补这一空白，提供与真实患者需求相符的控制性、可逆性和稳定性。</p>
</div><p>What makes Cadrenal's approach interesting is that none of this has been hyped. The Company has acted as a team focused on execution first. It spent months laying the groundwork, putting the structure in place so trials could progress to key milestones. Companies that prepare this thoughtfully usually do it for one reason. They expect their next phase to be bigger than the market expects.</p>
<div class="lb-trans"><p>Cadrenal 的做法之所以引人注目，是因为这一切并没有被炒作。公司作为一个团队，首先专注于执行。它花了几个月的时间打下基础，建立结构，以便试验能够顺利推进到关键里程碑。这样深思熟虑的准备通常是出于一个原因：他们期望下一阶段的成果超出市场的预期。</p>
</div><p><strong>A Pipeline That Grew While No One Was Looking</strong></p>
<div class="lb-trans"><p><strong>在无人关注时增长的管道</strong></p>
</div><p>Then came the expansion. Cadrenal added the Factor XIa program, designed to provide a new pathway into acute hospital care, where safer, more controlled anticoagulation would be welcomed immediately. This was not a cosmetic acquisition. It broadened the Company's mechanistic range and created opportunities that complement tecarfarin rather than compete with it. Suddenly, Cadrenal had a presence in both chronic and acute environments.</p>
<div class="lb-trans"><p>随后是扩展。Cadrenal 增加了 Factor XIa 项目，旨在为急性医院护理提供新的途径，安全、可控的抗凝治疗将在此受到欢迎。这并不是一次表面上的收购。它拓宽了公司的机制范围，并创造了与 tecarfarin 互补而非竞争的机会。突然间，Cadrenal 在慢性和急性环境中都有了存在。</p>
</div><p>The next move lifted the floor even higher. Cadrenal just acquired VLX-1005, a Phase 2 asset with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT). HIT is rare, dangerous, and urgently needs better options. A company of Cadrenal's size acquiring a program with that kind of regulatory positioning is uncommon. It is strategic. It puts Cadrenal in conversations that simply were not available to it a few quarters ago.</p>
<div class="lb-trans"><p>下一步更是提升了底线。Cadrenal 刚刚收购了 VLX-1005，这是一项针对肝素诱导的血小板减少症（HIT）的二期资产，获得了孤儿药和快速通道的认证。HIT 是罕见且危险的，迫切需要更好的治疗选择。像 Cadrenal 这样规模的公司收购具有这种监管定位的项目并不常见。这是战略性的。这使 Cadrenal 参与到几个月前根本无法接触的对话中。</p>
</div><p>All of this portfolio building happened while the stock continued to trade as if nothing had changed. The valuation could reflect an outdated picture, not the broader platform the Company now controls. That disconnect could create opportunity. Eventually, the market must realign because pipelines spanning multiple treatment settings do not remain hidden in microcap territory once clinical momentum builds.</p>
<div class="lb-trans"><p>所有这些投资组合的构建发生在股票继续交易，仿佛一切都没有改变。估值可能反映了过时的图景，而不是公司现在控制的更广泛的平台。这种脱节可能创造机会。最终，市场必须重新调整，因为跨越多个治疗环境的管道在临床势头建立后不会继续隐藏在微型公司领域。</p>
</div><p><strong>The Moment Before Momentum</strong></p>
<div class="lb-trans"><p><strong>动量之前的时刻</strong></p>
</div><p>Cadrenal is entering the stretch where quiet groundwork could turn into visible catalysts. Trial preparations are lining up. Program progression is advancing. Regulatory engagements start to matter more. Each step has the potential to reshape how investors view the Company. This is where a steady, disciplined strategy could pay off. The Company has done heavy lifting behind the scenes. Now the cycle shifts toward execution that the market can actually see.</p>
<div class="lb-trans"><p>Cadrenal 正进入一个安静的基础工作可能转变为明显催化剂的阶段。试验准备正在排队，项目进展顺利，监管互动开始变得更加重要。每一步都有潜力重塑投资者对公司的看法。这是一个稳定、严谨的战略可能会获得回报的地方。公司在幕后进行了大量的工作。现在，周期转向市场可以实际看到的执行。</p>
</div><p>The portfolio itself is structured to create leverage. Tecarfarin's chronic care positioning addresses the real-world needs of underserved patients for decades. The Factor XIa program moves Cadrenal into high-value hospital environments. VLX-1005 enters a space where even incremental improvement would command serious attention. Each asset strengthens the others by showing a company with a coherent vision rather than a scattershot pipeline.</p>
<div class="lb-trans"><p>投资组合本身的结构旨在创造杠杆。Tecarfarin 的慢性护理定位满足了数十年来被忽视患者的现实需求。Factor XIa 项目将 Cadrenal 带入高价值的医院环境。VLX-1005 进入了一个即使是微小的改进也会引起严重关注的领域。每个资产通过展示一个具有一致愿景的公司而加强了彼此，而不是一个杂乱无章的管道。</p>
</div><p>The quiet phase appears to be ending. Cadrenal built a platform that speaks louder with data than with headlines. CVKD still appears small on the screen, but the underlying architecture suggests otherwise. This is not a company waiting for relevance. It is a company preparing to express itself.</p>
<div class="lb-trans"><p>安静的阶段似乎即将结束。Cadrenal 建立了一个平台，用数据的声音比头条新闻更响亮。CVKD 在屏幕上仍然显得微小，但其基础架构却暗示着不同。这不是一家等待相关性的公司，而是一家准备表达自己的公司。</p>
</div><p><strong>About Cadrenal Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Cadrenal Therapeutics, Inc.</strong></p>
</div><p>Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.</p>
<div class="lb-trans"><p>Cadrenal Therapeutics, Inc.正在开发差异化产品，以填补当前急性和慢性抗凝管理在稀有和高风险患者群体中的关键空白。它目前拥有三项临床阶段资产：VLX-1005，一种针对 HIT 的首创二期 12-LOX 抑制剂；tecarfarin，一种用于肾功能障碍或左心室辅助装置（LVAD）患者的口服维生素 K 拮抗剂（VKA）；以及 frunexian，一种用于急性医院环境的静脉小分子 Factor XIa 拮抗剂。有关更多信息，请访问 https://www.cadrenal.com/ 并在 LinkedIn 上与公司联系。</p>
</div><p><strong>Safe Harbor</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potentially,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding Tecarfarin being designed to address that gap in predictable outcomes for high-risk patients with end-stage kidney disease and complex cardiac burdens with control, reversibility, and stability that align with real patient needs; spending months laying the groundwork, putting the structure in place so trials could progress to key milestones; companies expecting the next phase to be bigger than the market expects; the Factor XIa program providing a new pathway into acute hospital care, the valuation of the stock creating opportunity; the market eventually realigning; clinical momentum building; Cadrenal entering the stretch where quiet groundwork could turn into visible catalysts; trial preparations lining up; program progression beginning; regulatory engagements starting to matter more; each step having the potential to reshape how investors view the Company; this being where a steady, disciplined strategy could pay off; Tecarfarin's chronic care positioning addressing the real-world needs of underserved patients for decades; the quiet phase appearing to be ending; CVKD still appearing small on the screen, but the underlying architecture suggesting otherwise; and being a company preparing to express itself.. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, the ability to continue to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; including the ability to advance the clinical development of VLX-1005 for the treatment of HIT; the ability to use the acquisition of a Factor XIa portfolio to provide a new pathway to acute hospital care; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中关于未来预期、计划和前景的任何声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些声明包括关于 Tecarfarin 旨在解决高风险终末期肾病患者和复杂心脏负担的可预测结果差距的声明，控制、可逆性和稳定性与真实患者需求相一致；花费数月时间奠定基础，建立结构以便试验能够进展到关键里程碑；公司预计下一阶段将比市场预期更大；Factor XIa 项目提供进入急性医院护理的新途径，股票估值创造机会；市场最终重新调整；临床势头增强；Cadrenal 进入一个安静的基础工作阶段，可能转变为可见的催化剂；试验准备就绪；项目进展开始；监管互动开始变得更加重要；每一步都有可能重塑投资者对公司的看法；这是一个稳定、严谨的战略可能会获得回报的地方；Tecarfarin 的慢性护理定位满足数十年来服务不足患者的现实需求；安静阶段似乎即将结束；CVKD 在屏幕上仍然显得微小，但基础架构暗示并非如此；并且是一家准备表达自己的公司。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括继续推进新型治疗药物以治疗或预防高风险患者的血栓形成的能力；包括推进 VLX-1005 用于 HIT 治疗的临床开发的能力；利用收购 Factor XIa 组合提供急性医院护理新途径的能力；按时成功完成临床试验并实现预期的结果和利益的能力；获得产品候选商业化的监管批准或遵守持续监管要求的能力，以及在公司截至 2024 年 12 月 31 日的 10-K 表格年度报告和公司随后向证券交易委员会提交的文件中描述的其他风险因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，公司特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><em><strong>Accuracy &amp; Disclosure Statement:</strong> Hawk Point Media Group, LLC (HPM) has been retained by IR Agency, Inc. to provide press releases, editorial insights, and digital media production for Cadrenal Therapeutics. This content is sponsored. For services rendered from December 12, 2025 through December 16, 2025, HPM has been compensated ten thousand dollars (USD) via wire transfer for content creation and syndication related to Cadrenal Therapeutics. The information contained herein is based on sources believed to be accurate and reliable at the time of creation, including publicly available filings, company disclosures, and direct website content. This material is provided for informational purposes only and should not be interpreted as investment advice, a recommendation, or an offer to buy or sell any security.</em></p>
<div class="lb-trans"><p><em><strong>准确性与披露声明：</strong> Hawk Point Media Group, LLC (HPM) 已被 IR Agency, Inc. 聘请，为 Cadrenal Therapeutics 提供新闻稿、编辑见解和数字媒体制作。此内容为赞助内容。对于 2025 年 12 月 12 日至 2025 年 12 月 16 日提供的服务，HPM 已通过电汇获得一万美元（USD）的报酬，用于与 Cadrenal Therapeutics 相关的内容创作和传播。此处包含的信息基于在创作时被认为准确和可靠的来源，包括公开可用的文件、公司披露和直接网站内容。此材料仅供信息参考，不应被解读为投资建议、推荐或购买或出售任何证券的要约。</em></p>
</div><p><em>At the time of publication, HPM does not own, buy, sell, or trade securities of the companies covered. However, individuals or organizations that have retained HPM may hold shares of Cadrenal Therapeutics and may sell those shares during the coverage period. Such sales could place downward pressure on the stock price and result in financial loss for investors.</em></p>
<div class="lb-trans"><p><em>在发布时，HPM 不拥有、购买、出售或交易所覆盖公司的证券。然而，聘请 HPM 的个人或组织可能持有 Cadrenal Therapeutics 的股份，并可能在覆盖期间出售这些股份。这种销售可能对股价施加下行压力，并导致投资者财务损失。</em></p>
</div><p><em>Any reproduction, redistribution, or syndication of this content must include this disclosure in full. This statement is provided in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission's Endorsement Guides, and other applicable laws governing sponsored communications and paid investor content.</em></p>
<div class="lb-trans"><p><em>任何对该内容的复制、再分发或传播必须完整包含此披露。此声明是根据 1933 年证券法第 17(b) 条、联邦贸易委员会的认可指南以及其他适用法律提供的，适用于赞助通信和付费投资者内容。</em></p>
</div><p><strong>Contact for this content:</strong> info@hawkpointmedia.com</p>
<div class="lb-trans"><p><strong>联系方式：</strong> info@hawkpointmedia.com</p>
</div><p><strong>SOURCE:</strong> Cadrenal Therapeutics</p>
<div class="lb-trans"><p><strong>来源：</strong> Cadrenal Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMw" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1117023"/></p>

Cadrenal 的低调扩张策略开始引起广泛关注 | CVKD 股票新闻